Designed Multiple Ligands. An Emerging Drug Discovery Paradigm

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

2001 • 16,438 citations

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1997 • 9,861 citations

Molecular Properties That Influence the Oral Bioavailability of Drug Candidates

2002 • 6,592 citations

Adverse drug reactions: definitions, diagnosis, and management

2000 • 2,723 citations

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

2003 • 1,164 citations

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

2004 • 1,111 citations

A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport

2001 • 1,050 citations

The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance

1990 • 788 citations

Multicomponent therapeutics for networked systems

2005 • 749 citations

From magic bullets to designed multiple ligands

2004 • 689 citations

Excision of Deoxyribose Phosphate Residues by DNA Polymerase β During DNA Repair

1995 • 670 citations

Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy

1995 • 637 citations

Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib: New Pharmacological Opportunities Due to Related Binding Site Recognition

2003 • 438 citations

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

1988 • 429 citations

Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs

2003 • 415 citations

5-lipoxygenase inhibitory activity of zileuton.

1991 • 409 citations

Strategies to overcome resistance to targeted protein kinase inhibitors

2004 • 332 citations

Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.

1997 • 315 citations

Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? 1 1Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclooxygenase; LT, leukotriene; 5-LOX, 5-lipoxygenase; PG, prostaglandin; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsuphonyl)-phenyl-2(5H)-furanone; and DFP, diisopropyl fluorophosphate.

2001 • 277 citations

Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

1997 • 239 citations

Dual Metalloprotease Inhibitors: Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase

1997 • 197 citations

The Effects of a Selective D4 Dopamine Receptor Antagonist (L-745,870) in Acutely Psychotic Inpatients With Schizophrenia

1997 • 195 citations

From Models to Molecules: Opioid Receptor Dimers, Bivalent Ligands, and Selective Opioid Receptor Probes

2001 • 185 citations

Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity

1994 • 160 citations

The 5-HT 3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist

2001 • 158 citations

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

2002 • 152 citations

Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation

1998 • 145 citations

Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors

1996 • 140 citations

Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes

2004 • 140 citations

Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system.

1998 • 126 citations

The biochemical pharmacology of thromboxane synthase inhibition in man.

1985 • 122 citations

Duloxetine (Cymbalta™), a dual inhibitor of serotonin and norepinephrine reuptake

2003 • 118 citations

The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain

1996 • 118 citations

(6,7-Diaryldihydropyrrolizin-5-yl)acetic Acids, a Novel Class of Potent Dual Inhibitors of Both Cyclooxygenase and 5-Lipoxygenase

1994 • 118 citations

A Bivalent Ligand (KDAN-18) Containing δ-Antagonist and κ-Agonist Pharmacophores Bridges δ₂ and κ₁ Opioid Receptor Phenotypes

2004 • 114 citations

A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor

1993 • 112 citations

(3-Substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

1999 • 105 citations

Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of .omega.-pyridylalkenoic acids

1985 • 99 citations

3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents

1996 • 89 citations

R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo

1989 • 89 citations

Serotonin (5-HT) enhances hippocampal noradrenaline (NA) release: Evidence for facilitatory 5-HT receptors within the CNS

1986 • 85 citations

A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

2003 • 84 citations

Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2‘-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics

2004 • 80 citations

7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as Dual Inhibitors of Src and Abl Kinases

2004 • 71 citations

A New Class of Ibuprofen Derivatives with Reduced Gastrotoxicity

2001 • 71 citations

Rationally designed, potent competitive inhibitors of leukotriene biosynthesis

1984 • 71 citations

First dual NK1 antagonists–serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants

2002 • 69 citations

Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11

1993 • 68 citations

Synthesis and Activity of a New Methoxytetrahydropyran Derivative as Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitor

2002 • 65 citations

Combination antihypertensive drugs: recommendations for use.

2000 • 59 citations

Pyrrolo[1,3]benzothiazepine-Based Serotonin and Dopamine Receptor Antagonists. Molecular Modeling, Further Structure−Activity Relationship Studies, and Identification of Novel Atypical Antipsychotic Agents

2003 • 59 citations

Dual antagonists of platelet-activating factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines

1991 • 58 citations

Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT_1A and Serotonin Transporter Affinity within a Class of N-Aryloxyethylindolylalkylamines

2004 • 57 citations

Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 2: Asymmetric synthesis and biological evaluation

2002 • 55 citations

A Novel Pharmacological Approach to Treating Cardiac Ischemia

2000 • 55 citations

3,4-Dihydro-2H-benzoxazinones are 5-HT1A receptor antagonists with potent 5-HT reuptake inhibitory activity

2004 • 54 citations

1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents

1991 • 53 citations

Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen‐2)27), hypertensive rats

1995 • 52 citations

Design of Selective Peptidomimetic Agonists for the Human Orphan Receptor BRS-3

2003 • 51 citations

Discovery of N-Isoxazolyl Biphenylsulfonamides as Potent Dual Angiotensin II and Endothelin A Receptor Antagonists

2002 • 50 citations

Dual D₂-Receptor and β₂-Adrenoceptor Agonists for the Treatment of Airway Diseases. 1. Discovery and Biological Evaluation of Some 7-(2-Aminoethyl)- 4-hydroxybenzothiazol-2(3H)-one Analogues

1998 • 49 citations

Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate.

1992 • 48 citations

Preparation of (R)-(+)-N-[3-[5-[(4-Fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.

1995 • 45 citations

Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists

2004 • 43 citations

Antiinflammatory 2,6-di-tert-butyl-4-(2-arylethenyl)phenols

1989 • 42 citations

[(3-Pyridylalkyl)piperidylidene]benzocycloheptapyridine Derivatives as Dual Antagonists of PAF and Histamine

1994 • 38 citations

6,6-Disubstituted hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors

1994 • 36 citations

5-Lipoxygenase inhibitors with histamine H 1 receptor antagonist activity

2004 • 36 citations

2,6-Di-tert-butyl-4-(2′-thenoyl)phenol(R-830): A novel nonsteroidal anti-inflammatory agent with antioxidant properties

1982 • 35 citations

Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine

2003 • 34 citations

Novel Dual Inhibitors of 5-Lipoxygenase and Thromboxane A2 Synthetase: Synthesis and Structure-Activity Relationships of 3-Pyridylmethyl-Substituted 2-Amino-6-hydroxybenzothiazole Derivatives

1994 • 34 citations

Potent dual antagonists of endothelin and angiotensin II receptors derived from α-phenoxyphenylacetic acids (Part III)

1995 • 34 citations

Design and synthesis of novel PPARα/γ/δ triple activators using a known PPARα/γ dual activator as structural template

2003 • 33 citations

Dual metalloprotease inhibitors. I. constrained peptidomimetics of mercaptoacyl dipeptides

1994 • 33 citations

Structure−Activity Studies for a Novel Series ofN-(Arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines Possessing Dual 5-HT Uptake Inhibiting and α₂-Antagonistic Activities

1997 • 32 citations

Studies toward the discovery of the next generation of antidepressants. Part 2: Incorporating a 5-HT1A antagonist component into a class of serotonin reuptake inhibitors

2002 • 32 citations

Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action

1999 • 31 citations

Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors

1996 • 30 citations

Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for μ opioid and I2-imidazoline receptors: synthesis and pharmacological screening

2002 • 29 citations

Histamine antagonists and asthma

1982 • 28 citations

N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities

2002 • 26 citations

Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin

2002 • 25 citations

Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 1: Identification and structure–activity relationships

2002 • 24 citations

Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for μ-opioid receptors and I2-imidazoline binding sites

2003 • 20 citations

NCX-4016 NicOx.

2003 • 19 citations

Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression

2003 • 19 citations

Design and synthesis of new potent, silent 5-HT1A antagonists by covalent coupling of aminopropanol derivatives with selective serotonin reuptake inhibitors

1998 • 19 citations

Dibenz[b,e]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity. 1

1993 • 18 citations

SAR development of a selective 5-HT1D antagonist/serotonin reuptake inhibitor lead using rapid parallel synthesis

2004 • 17 citations

Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease

2004 • 17 citations

Parallel synthesis of 3-aryloxy-2-propanolamines and evaluation as dual affinity 5-HT1A and 5-HT re-uptake ligands

1999 • 17 citations

Synthesis and sar of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activity

1997 • 16 citations

Novel selective and potent 5-HT reuptake inhibitors with 5-HT1D antagonist activity: chemistry and pharmacological evaluation of a series of thienopyran derivatives

2004 • 16 citations

Synthesis and pharmacological evaluation of some amino-acid-containing cyproheptadine derivatives as dual antagonists of histamine H1- and leukotriene D4-receptors

1997 • 16 citations

Synthesis and pharmacological evaluation of highly potent dual histamine H2 and gastrin receptor antagonists

1996 • 15 citations

New targets for antipsychotics

2002 • 12 citations

Thromboxane modulating agents. 1. Design of 1-[(arylsulfonyl)amino] alkylindole derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.

1995 • 11 citations

Biphenyl derivatives as novel dual NK1/NK2-receptor antagonists

2002 • 10 citations

Ezetimibe + simvastatin (Merck/Schering-Plough).

2004 • 8 citations

Synthesis and pharmacological characterization of A-80426: A putative novel antidepressant combining α-2 antagonism with 5-HT uptake inhibition

1995 • 7 citations

Mobilization of Peripheral Blood Progenitor Cells Following CHOP Treatment Combined with Delayed Granulocyte Colony-Stimulating Factor Administration in Patients with Non-Hodgkin's Lymphoma

1996 • 6 citations

Quetiapine: a new atypical antipsychotic for the treatment of schizophrenia.

1998 • 3 citations

Submitting articles to the BMJ

2003 • 2 citations

Folic acid analogs lacking the 2-carbon are substrates for folylpolyglutamate synthetase and inhibit cell growth

1991 • 2 citations

ChemInform Abstract: Dibenz(b,e)oxepin Derivatives: Novel Antiallergic Agents Possessing Thromboxane A2 and Histamine H1 Dual Antagonizing Activity. Part 1.

1994 • 2 citations